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Summary Objective: Effective empirical antimicrobial therapy has led to a better
outcome for febrile neutropenic patients. Guidelines are based mainly on expert opinion,
current practice and some clinical trials. Clinical study evidence and meta-analyses of
treatment options are reviewed and a treatment strategy recommended.
Results: Piperacillin-tazobactam, meropenem and imipenem have demonstrated signiﬁcant
superiority over ceftazidime and cefepime. Oral ciproﬂoxacin plus amoxicillin-clavulanic
acid is as effective as IV therapy for low risk patients. In high risk patients, additional
aminoglycoside does not improve clinical success but increases nephrotoxicity. In clinically
stable patients (no CVC, soft tissue, pulmonary, fungal or viral infection), additional
glycopeptide is unnecessary.
The Bonn treatment strategy is oral combination therapy (ﬂuoroquinolone and amoxicillin-
clavulanic acid) in low risk patients. Low risk patients who cannot take oral medication
or high risk patients without signiﬁcant skin, soft tissue or CVC infection receive
IV monotherapy with piperacillin-tazobactam. Piperacillin-tazobactam has been used for
more than a decade with no increase in bacterial resistance.
Conclusion: Antimicrobial therapy selection should be based on several factors including
the likely pathogen, local antimicrobial susceptibility patterns, patient infection site, risk
assessment, clinical stability, organ dysfunction, previous antimicrobial therapy, and cost.
© 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.
Introduction
Progress in the therapy and supportive care of patients
with haematological malignancies has led to a gradual
improvement in survival rates. Overall, the 5-year survival
rate of patients 55 yrs with newly diagnosed acute
myeloid leukaemia (AML) treated on Eastern Cooperative
Oncology Group (ECOG) protocols has risen from 11% in
1973–1979 to 37% in 1989–1997 1. Improvements in
mortality and morbidity are associated with the use
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of more aggressive chemotherapy, but at the cost of
more severe side effects, such as neutropenia. The rate
and degree of decline in neutrophils and the duration
of neutropenia have been shown to inﬂuence the risk
of infection in AML. Because the immune response is
muted, the signs and symptoms of infection may not
be apparent and fever is frequently the ﬁrst, and in
most cases, the only sign of infection. Fever during
neutropenia is associated with a mortality rate of
5–10%, and more than 80% of AML patients treated with
chemotherapy have at least one episode of fever during
the neutropenic period 2.
Currently, diagnostic tests are not rapid, sensitive or
speciﬁc enough to distinguish a microbiological cause
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Table 1
Guidelines for ﬁrst-line empirical antibiotic therapy of fever in neutropenic patients
Guideline Low risk patients
Monotherapy Combination therapy
High risk patients
Monotherapy Combination therapy
Germany (2003) 4 Ciproﬂoxacin or
levoﬂoxacin
Oﬂoxacin +
amoxicillin-clavulanic acid
Ceftazidime, cefepime,
piperacillin-tazobactam,
carbapenem
Acylaminopenicillin + AMG,
cephalosporin III/IV + AMG
USA – IDSA (2002) 5 None Ciproﬂoxacin +
amoxicillin-clavulanic acid
Ceftazidime, cefepime,
carbapenem
Acylaminopenicillin + AMG,
cephalosporin III/IV + AMG
USA – NCCN (2005) 6 None Ciproﬂoxacin +
amoxicillin-clavulanic acid
(or clindamycin)
Ceftazidime, cefepime,
piperacillin-tazobactam,
carbapenem
Acylaminopenicillin + AMG,
cephalosporin III/IV + AMG
Spain (2001) 7 None Levoﬂoxacin +
amoxicillin-clavulanic acid
or cefprozil + ciproﬂoxacin
Previous FQ therapy:
ceftriaxone + ceftibuten
Ceftazidime, cefepime,
piperacillin-tazobactam,
carbapenem
None
of fever from other causes. The Gram-positive cocci
account for 60–70% of bacteria causing fever with
coagulase-negative staphylococci (CoNS) then viridans
streptococci (Streptococcus mitis, Streptococcus salivarius
and Streptococcus millerei) followed by Staphylococcus
aureus and Enterococcus faecium 3. Gram-negative bacilli
account for the remainder and include Escherichia
coli, Pseudomonas aeruginosa, Enterobacter species and
Stenotrophomonas maltophilia. Prompt administration of
effective empirical broad-spectrum antimicrobial therapy
is essential for managing febrile neutropenia and has led
to an improved outcome.
Clinical classiﬁcation of neutropenic
fever
Deﬁnitions of neutropenic fever vary from centre to
centre. German guidelines deﬁne neutropenic fever as an
oral temperature of 38.3ºC measured once or 38.0ºC
sustained for at least 1 hour or measured twice within
12 hours, in a patient with neutropenia deﬁned by a
neutrophil count (segments and bands) of <0.5×109/L
(<500 /mL or <1.0×109/L (<1000/mL), with a predicted
decline to 0.5×109/L (500/mL) within the next 2 days 4.
Deﬁnition of risk factors
Patients are differentiated into risk categories for antimi-
crobial therapy according to the duration of neutropenia
and the presence of risk factors for serious infection.
Patients are classiﬁed as at low risk when neutropenia
is of short duration (5 days), there is no infection
of the central nervous system (CNS) or central venous
catheter (CVC) or pneumonia, there are no signs of sepsis
or shock, the ECOG performance status is 0–2, there is no
severe comorbidity and there are adequate social, medical
and intellectual resources (including ability to take oral
medication and adequate ﬂuid). These patients may be
considered for oral therapy. Those with neutropenia of
longer duration are classiﬁed as intermediate (6–9 days) or
high risk (10 days) and are treated with intravenous (IV)
therapy.
Guidelines for empirical therapy
Guidelines for empirical therapy of febrile neutropenia
have been published in several countries based mainly
on expert opinion, current practice and some clinical
trials (Table 1). German guidelines recommend empirical
monotherapy or combination therapy with antipseu-
domonal and antistreptococcal agents 4. Low risk patients
suitable for oral therapy may receive ciproﬂoxacin or
levoﬂoxacin as monotherapy or combination therapy with
oﬂoxacin and amoxicillin-clavulanic acid. Intermediate
and high risk patients should receive IV monotherapy
with ceftazidime, cefepime, piperacillin-tazobactam or a
carbapenem or combination therapy with any of these
b-lactams plus a single dose of an aminoglycoside (AMG).
In severe mucositis or suspected CVC associated infection,
a glycopeptide may be added. The regimen is modiﬁed
after 72–96 hours of therapy if fever persists, with
the exception of CoNS infections, which take longer to
respond. In intermediate and high risk patients, initial
monotherapy may require the addition of an AMG; or
initial carbapenem monotherapy may be followed by a
ﬂuoroquinolone and/or a glycopeptide. After resolution of
fever to <38ºC, treatment is continued for 7 days if the
neutrophil count is <1×109/L (<1000 cells/mL) or 2 days if
it is >1×109/L (>1000 cells/mL).
The Infectious Diseases Society of America (IDSA)
guidelines (2002) recommend oral empirical therapy with
ciproﬂoxacin and amoxicillin-clavulanic acid for low risk
patients 5 or IV therapy with either cefepime, ceftazidime
or a carbapenem. Piperacillin-tazobactam is also men-
tioned as an effective monotherapy, but not recommended
as there were insufﬁcient data at the time. Combination
therapy consists of an AMG (gentamicin, tobramycin,
amikacin) together with an antipseudomonal penicillin
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(ticarcillin-clavulanic acid or piperacillin-tazobactam),
cefepime, ceftazidime or carbapenem.
The European Organisation for Research and Treatment
of Cancer (EORTC) and the National Cancer Institute of
Canada suggest that vancomycin should not generally be
used as empirical therapy because of the association
between its excessive use in hospitals and the emergence
of vancomycin-resistant enterococci (VRE). Alternatives
requiring more study include teicoplanin (not available
outside Europe), linezolid or quinupristin-dalfopristin.
Low risk patients on IV therapy who have no subsequent
complications can be changed after 48 hours to oral
ciproﬂoxacin and amoxicillin-clavulanic acid, and all
patients who become afebrile in 3–5 days continue the
same therapy. In persistent fever, the patient is reassessed
at day 3. If there is no clinical deterioration the same
therapy is continued, but when there is progression of
the infection or clinical instability, the therapy should
be changed with the addition of an antifungal agent
empirically if the patient is still febrile after 5 days. If
the patient is afebrile and clinically stable, therapy can
be stopped when the neutrophil count exceeds 0.5×109/L
(500/mL) for 2 consecutive days and the patient has been
afebrile for 48 hours. If the patient is afebrile and still
neutropenic but clinically stable therapy can be stopped
after 5–7 days.
More recent US guidelines have been compiled by
the National Comprehensive Cancer Network (2005) 6.
Low risk patients receive oral combination therapy only
with ciproﬂoxacin and amoxicillin-clavulanic acid (or clin-
damycin when there is penicillin allergy). The Panel recom-
mends 3 evidence-based approaches to IV therapy. Firstly,
monotherapy with piperacillin-tazobactam, a carbapenem
(imipenem-cilastatin or meropenem) or a cephalosporin
(ceftazidime or cefepime), though recent studies have
shown that some Gram-negative bacilli, including Pseu-
domonas aeruginosa, are developing resistance to ce-
fepime and ceftazidime. Secondly, combination therapy
of an AMG together with either an antipseudomonal
penicillin (with or without a b-lactamase inhibitor) or
an extended-spectrum antipseudomonal cephalosporin.
Ciproﬂoxacin with an antipseudomonal penicillin can also
be given. Thirdly, monotherapy or combination therapy
plus IV vancomycin. The Panel recommends quinpristin-
dalfopristin, linezolid and daptamycin limited to speciﬁc
situations such as the involvement of a vancomycin-
resistant enterococcus or when vancomycin is not an
option.
Initial empirical therapy in clinically unstable patients
should comprise a combination of a carbapenem, an
AMG and vancomycin, depending on local susceptibility
patterns, and a cephalosporin or penicillin with either an
AMG or ciproﬂoxacin, if there is a history of infection
due to Pseudomonas aeruginosa. Therapy can be stopped
for patients who become afebrile for at least 24 h soon
after initiation of therapy if neutropenia has resolved.
Patients who become afebrile but remain neutropenic
should receive therapy until neutrophil recovery. Patients
who remain neutropenic with no focus of infection and
are afebrile for 7–14 days may either discontinue therapy
or change to oral therapy until neutropenia resolves.
Persistent fever is reassessed after 4 days therapy, and
recurrent fever may require a change in therapy or the
addition of an antifungal agent.
Spanish guidelines (2001) recommend oral therapy for
low risk patients not previously given ﬂuoroquinolone ther-
apy. Therapy can consist of levoﬂoxacin and amoxicillin-
clavulanic acid, or ciproﬂoxacin and cefprozil. Ceftriaxone
and ceftibuten with or without teicoplanin is recommended
for those previously treated with a ﬂuoroquinolone 7.
Initial IV monotherapy with cefepime, piperacillin-
tazobactam, meropenem or imipenem is recommended.
Additional antimicrobial agents are recommended for
several indications. Addition of a glycopeptide (vancomycin
or teicoplanin) is indicated for CoNS infection or a
CVC infection, amikacin for colonisation with the Gram-
negative bacilli, Pseudomonas aeruginosa or Acinetobac-
ter spp., a glycopeptide (vancomycin or teicoplanin) and
amikacin for septic shock, and initial treatment with
aztreonam or amikacin and a glycopeptide when there is
allergy to penicillin. If infection is due to Pseudomonas
aeruginosa amikacin or ciproﬂoxacin is added to the initial
regimen and/or fever persists after 3–5 days treatment
and no microbiologically deﬁned infection is found, an
aminoglycoside or glycopeptide or both are added. If
fever persists for 5–7 days addition of an antifungal
(amphotericin B) is considered.
Evidence based evaluation of combination
versus monotherapy
The Cochrane Review of 15 randomised controlled trials
of oral versus IV therapy found that oral ﬂuoroquinolone
monotherapy or combination therapy produced compa-
rable results 8. The analysis did not produce any data
to support any particular regimen but suggested it was
prudent to employ a combination of a ﬂuoroquinolone
with a second antibiotic active against Gram-positive
organisms. Oral empirical therapy with ciproﬂoxacin and
amoxicillin-clavulanic acid was found to be as safe and as
effective as IV therapy for low risk patients 9-11. However,
most guidelines recommend combination therapy with a
b-lactam plus an AMG as an alternative to a b-lactam alone.
Many studies have compared the two approaches, but there
is no consensus on the superiority of one over the other
(Table 2).
Aminoglycosides, clinical outcomes:
survival and adverse reactions
A systemic review of clinical trials compared the efﬁcacy
of monotherapy with combinations containing AMG 12. A
meta-analysis of pooled data from 4795 febrile neutropenic
episodes in 29 clinical trials and a subset of 1029
bacteraemic episodes was carried out by both Peto ﬁxed
and Der Simonian and Laird random effects models. No
statistical heterogeneity between the trials was detected.
The outcome measure was clinical treatment failure
deﬁned as modiﬁcation of the initially allocated regimen
or death during treatment. The pooled odds ratio (OR)
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Table 2
Evidence based studies of ﬁrst-line empirical antibiotic therapy of fever in neutropenic patients
References Trials (patients) Findings
Oral vs IV therapy Vidal et al. 8
Innes et al. 9
Kern et al. 10
Freifeld et al. 11
15 Oral ciproﬂoxacin and amoxicillin-clavulanic acid is
as effective as IV therapy in low risk patients.
Monotherapy vs combination + AMG Furno et al. 12 29 (4795) Monotherapy is as effective as combination
therapy + AMG
b-lactam monotherapy vs
b-lactam–AMG combination therapy
Paul et al. 13 47 (7807) Broad spectrum b-lactam is as effective as
combination therapy + AMG
Cefepime monotherapy vs comparators Paul et al. 14 33 Ceftazidime, piperacillin-tazobactam, and
carbapenems are more effective than cefepime
Empirical use of glycopeptides Wade and
Glasmacher 15
2 (279) A glycopeptide is not necessary in clinically stable
patients without CVC, soft tissue or pulmonary
infection, fungal or viral infection but should be
added in CVC or soft tissue infection.
of clinical failure with monotherapy versus combination
therapy for all febrile episodes was 0.88 (95%CI: 0.78–0.99;
p < 0.05) by the ﬁxed effects model and 0.87 (95%CI:
0.75–1.01) by the more conservative random effects model.
For bacteraemic episodes, the pooled OR was 0.70 (95%CI:
0.54–0.92; p < 0.05) by the ﬁxed effects model and 0.72
(95%CI: 0.54–0.95) by the random effects model. There was
a tendency to favour monotherapy in all of the subgroup
analyses and there was a higher rate of adverse events,
mainly nephrotoxicity, in the combination therapy groups.
It was concluded that monotherapy was as effective as
combination therapy with AMG. The relative risk (RR) of
treatment failure with monotherapy was reduced overall
by 12% and by 30% for bacteraemic episodes.
A second meta-analysis of data from 7807 patients
in 47 clinical trials comparing the efﬁcacy of b-lactam
monotherapy versus combination therapy with a b-lactam
plus an AMG was carried out using an intent to treat (ITT)
approach 13. RRs were pooled with the random effects
model. The outcome measure was all-cause fatality. The
mean all-cause fatality was 6.2% and overall, there
was no signiﬁcant difference between monotherapy and
combination therapy (RR 0.85, 95%CI: 0.72–1.02; ns). For
success of treatment there was a signiﬁcant advantage
for monotherapy (0.92, 95%CI: 0.85–0.99). In 5 trials
using the same b-lactam antibiotic in both arms, there
was no signiﬁcant difference between monotherapy and
combination therapy (0.73, 95%CI: 0.49–1.08) but there
was a major advantage for monotherapy in trials comparing
different b-lactams (0.87, 95%CI: 0.80–0.93). There was a
small advantage for monotherapy when data for treatment
failure was combined from all 47 studies (RR 0.92, 95%CI:
0.85–0.99; ns), but signiﬁcant heterogeneity was detected
among the trials. There was no signiﬁcant difference in
treatment failure between monotherapy and combination
therapy in 9 trials that compared the same b-lactam in
both arms (RR 1.12, 95%CI: 0.96–1.29; ns). However, there
was signiﬁcant beneﬁt for monotherapy in trials comparing
different beta-lactams (0.87, 95%CI: 0.80–0.93). There
was also a signiﬁcant advantage for monotherapy for
patients with documented infection and haematological
malignancies. In the combination treatment group, adverse
events were signiﬁcantly more common with an important
difference in the development of renal failure (0.49,
95%CI: 0.36–0.65) that was not inﬂuenced by single daily
administration of AMG. Discontinuation of therapy because
of an adverse event was also more common (0.57, 95%CI:
0.36–0.91). It was concluded that there is no clinical
advantage for combination therapy which is associated
with a signiﬁcantly higher rate of adverse events, mainly
nephrotoxicity. Hence monotherapy with a broad-spectrum
b-lactam antibiotic should be regarded as standard care in
patients with febrile neutropenia.
Glycopeptides: summary of
meta-analyses
Gram-positive cocci are the most commonly identiﬁed
cause of infection of febrile neutropenic patients, and
the b-lactams and carbapenems employed for empirical
therapy lack in-vitro activity against many of the
species involved. Hence many clinicians consider that
glycopeptides should be used empirically 16. Indeed,
empirical modiﬁcation of the therapy regimen is still
standard practice in many centres, most frequently with
a glycopeptide, on the basis of persistent fever for a
period as short as 48–96 hours 17. There is considerable
debate about the use of empirical glycopeptides because
of the growing awareness of the development of resistance
among enterococci, Staphylococcus aureus and CoNS, the
potential for nephrotoxicity and their high cost.
Most guidelines stress that vancomycin should not be
considered as a routine component of initial empirical
therapy, but its use should be limited to certain indications
including clinically deﬁned CVC infections (usually caused
by CoNS); high level b-lactam resistance, Gram-positive
bacteraemia, known colonisation with b-lactam-resistant
pneumococci or methicillin-resistant Staphylococcus au-
reus (MRSA), previous prophylaxis with ﬂuoroquinolones
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such as ciproﬂoxacin or cotrimoxazole (trimethoprim-
sulfamethoxazole), or the presence of hypotension or
septic shock.
In a double-blind study of 763 neutropenic patients,
165 remained febrile after 48–60 hours of empirical
piperacillin-tazobactam monotherapy and were randomly
allocated vancomycin (86 episodes) or placebo (79) as
additional therapy 17. Resolution of fever was observed
in 82/86 (95%) vancomycin and 73/79 (92%) placebo
treated episodes. Overall, resolution of fever without any
modiﬁcation of therapy occurred in 458/677 episodes (68%:
ns) with a median time to defervescence of 4.3 days
(95%CI: 3.5–5.1 days).
Adverse events deﬁnitely or probably associated with
study medication were seen for 9 patients (10%) treated
with vancomycin and included rash (3), pruritis (2), nephro-
toxicity (2), lip swelling (1) and red man syndrome (1);
and for 3 given placebo (4%) including pseudomembranous
colitis, diarrhoea and rash.
In a second double-blind study, neutropenic patients who
remained febrile after 72–96 hours of empirical imipenem
monotherapy were randomised to additionally receive
teicoplanin (56 patients) or placebo (58) 17. Resolution of
fever within 72 hours occurred in 25 teicoplanin (44.6%)
and 27 placebo treated patients (46.6%).
A small meta-analysis of the two trials showed that in
279 patients, no difference for resolution of fever without
modiﬁcation of therapy was found (Peto OR 0.795; 95%CI:
0.446–1.605; p = 0.605) or in infectious disease related
mortality (Peto OR 1.984; 95%CI: 0.467–4.188; p = 0.312) 15.
The evidence suggests that initial empirical therapy can
be continued, and the addition of a glycopeptide is
unnecessary, for clinically stable patients who do not have
a CVC, soft tissue or pulmonary infection, a fungal or viral
infection.
Piperacillin-tazobactam: combination
versus monotherapy
One multicentre, double-blind, placebo-controlled trial
has compared empirical piperacillin-tazobactam monther-
apy and piperacillin-tazobactam and amikacin combina-
tion therapy for 364 and 369 patients, respectively 18.
Piperacillin-tazobactam monotherapy was as effective as
combination therapy according to all efﬁcacy parameters
examined. The overall success rate was similar in each
treatment arm; monotherapy (49%) and combination
therapy (53%), [95%CI: – 11–3; p = 0.2]. The overall
distribution of time to defervescence and to failure
was similar (p = 0.6 and 0.9, respectively). Treatment
success in the ITT population for monotherapy was 49%
and combination therapy 51% (p = 0.6). Monotherapy was
discontinued for 2 patients because of skin rash and
gastrointestinal disturbance, and combination therapy for
5 patients because of skin rash (2), nephrotoxicity (2) and
hypersensitivity (1). The study concluded that empirical
monotherapy with piperacillin-tazobactam was as efﬁca-
cious as the combination of piperacillin-tazobactam and
an AMG for the treatment of high-risk, febrile neutropenic
patients.
Data from consecutive cohorts of neutropenic patients
with haematological malignancies at the University of
Bonn treated with piperacillin-tazobactam monotherapy
or piperacillin-tazobactam plus gentamicin have demon-
strated a similar result. The response rate with or without
modiﬁcation was 57% in monotherapy patients versus 54% in
combination therapy patients (p = 0.774) 19.
Treatment options for monotherapy
Current guidelines recommend ceftazidime, cefepime,
piperacillin-tazobactam, imipenem and meropenem for
empirical monotherapy. Ceftazidime is not recommended
in the Spanish guidelines and in the USA, piperacillin-
tazobactam is not recommended in IDSA guidelines (2002)
because of lack of clinical experience, but is recommended
in later NCCN guidelines (2005).
In a meta-analysis and systemic review of randomised,
controlled trials, the main analysis of all-cause mortality
comparing cefepime with a comparator showed that
there was a non-signiﬁcant tendency in the subgroups
in favour of the comparator 20. However, there was a
signiﬁcantly higher mortality rate associated with cefepime
than with other b-lactams (ceftazidime, carbapenems and
piperacillin-tazobactam); 96 versus 66 deaths, respectively
(RR 1.44, 95%CI: 1.06–1.94; p = 0.02). There were no
methodological problems, no statistical heterogeneity and
no publication bias (symmetrical funnel plot) and the
effect is consistent in studies with adequate allocation
concealment or generation and ITT analysis. A higher
mortality rate was associated with a lower dose of
cefepime (<6 g/day), [RR 2.01, 95%CI: 0.87–5.08] and a
signiﬁcant mortality difference was also seen in full dose
studies [RR 1.73, 95%CI: 1.12–2.66].
A further meta-analysis currently includes 37 studies
and 8676 febrile neutropenic patients 21. The main
outcome was response without treatment modiﬁcation,
and a survival difference was not identiﬁed. The analysis
included published survival data only, whereas the
meta-analysis of Paul et al. 20 included additional data
retrieved from authors. Signiﬁcant heterogeneity between
trials was not detected. Ceftazidime was found to
be inferior to piperacillin-tazobactam, meropenem and
imipenem-cilastatin (RR for failure of treatment without
modiﬁcation 0.88, 95%CI: 0.83–0.92). There was a clear
advantage for piperacillin-tazobactam use in comparison
to ceftazidime (RR 0.81, 95%CI: 0.72–0.91; p = 0.04) and
the same trend was seen in comparison to cefepime
(0.94, 95%CI: 0.86–1.03; p = 0.93) 22-26,14,27,28. Overall there
was a signiﬁcant advantage for piperacillin-tazobactam
compared to all cephalosporins (0.89, 95%CI: 0.83–0.95;
p = 0.19), with 11% reduction of the RR of treatment failure
(Table 3).
In a randomised, open label, controlled study, ﬁrst
line monotherapy with piperacillin-tazobactam in 265
febrile neutropenic patients was compared to cefepime
in 263 patients 20. At end of treatment, the clinical
success rate in ITT patients was signiﬁcantly superior
in patients treated with piperacillin-tazobactam (45.3%)
than cefepime (35.9%), p = 0.04. Adverse events in
S14 A. Glasmacher, M. von Lilienfeld-Toal
Table 3
Clinical trials with piperacillin-tazobactam in neutropenic patients: relative risk of treatment failure without modiﬁcation
Clinical trial Cephalosporin III
(n/N)
Piperacillin-tazobactam
(n/N)
RR (ﬁxed) 95%CI Favours PipTaz over ceph III
Piperacillin-tazobactam versus ceftazidime
Cometta et al. 1995 22 132/342 168/364 0.84 (0.70, 0.99) +
Marie et al. 1995 23 37/94 54/94 0.69 (0.50, 0.93) +
Hess et al. 1998 24 40/48 39/48 1.03 (0.85, 1.23) –
Marie et al. 1999 25 52/114 83/133 0.73 (0.57, 0.93) +
Subtotal (95% CI) 598 639 0.81 (0.72, 0.91) +
Piperacillin-tazobactam versus cefepime
Bohme et al. 1998 26 19/49 22/51 0.90 (0.56, 1.44) +
Cornely et al. 2001 14 68/177 70/176 0.97 (0.74, 1.25) +
Sanz et al. 2002 27 212/432 222/435 0.96 (0.84, 1.10) +
Bow et al. 2003 28 155/263 172/265 0.91 (0.79, 1.04) +
Subtotal (95%CI) 921 927 0.94 (0.86, 1.03) +
Overall total (95% CI) 1519 1566 0.89 (0.83, 0.95) +
both treatment groups were most frequently rash and
diarrhoea. It was concluded that piperacillin-tazobactam
monotherapy was as safe and at least as efﬁcacious as
cefepime.
Treatment strategy at the University of
Bonn
The clinical classiﬁcation of neutropenic fever used in Bonn
differs slightly from that used in most guidelines (Figure 1).
Patients are initially categorised as low or high risk.
High risk patients are differentiated into those with
clinically or microbiologically deﬁned infection whereby
the focus of infection can be determined (pneumonia,
neutropenic enterocolitis, urinary tract infection, skin and
soft tissue infection or a CVC infection) and those with
unexplained fever. Treatment can be adapted according
to whether this information is available, but it is not
necessary for empirical therapy. The criteria for oral
therapy are similar to the German guidelines. In Bonn, a
patient with an expected duration of neutropenia of less
than ﬁve days, who is clinically stable and has not received
very intensive chemotherapy, may receive oral therapy.
Oral therapy has been shown to be effective for patients
with 5–10 days neutropenia after a more intensive course
of chemotherapy for lymphoma.
A low risk patient able to take oral therapy receives
a ﬂuoroquinolone and amoxicillin-clavulanic acid (or sul-
tamicillin). IV monotherapy with piperacillin-tazobactam is
administered to those patients who are unable to take oral
medication and to high risk patients when a glycopeptide is
not required. A glycopeptide is added if there is clinically
signiﬁcant skin and soft tissue or CVC infection. If fever is
not resolved after 3–4 days of therapy, the patient is re-
evaluated and a CT scan is performed. When the patient
is stable, with no pulmonary inﬁltrates and no soft tissue
Figure 1. Initial empirical antimicrobial therapy in neu-
tropenic fever in the Department of Haematology and
Oncology, University of Bonn.
infection, therapy is continued for 7–8 days, and then
changed to a different regimen if the patient remains
clinically stable.
Piperacillin-tazobactam has been used as initial monother-
apy in Bonn for more than 10 years with no increase of
bacterial resistance despite its intensive use (Figure 2). The
susceptibility rates in 2005 for Escherichia coli were 97%,
Pseudomonas aeruginosa (90%), Klebsiella pneumoniae
(94%) and Serratia marcescens (87%), [Molitor E, personal
communication].
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Figure 2. Susceptibility rates after 10 years of piperacillin-
tazobactam use in the Department of Internal Medicine,
University of Bonn (E. Molitor, data on ﬁle, 2005).
Choice of monotherapy
Piperacillin-tazobactam, meropenem or imipenem are
good choices for initial empirical antibiotic therapy as they
have demonstrated signiﬁcant superiority over ceftazidime
and cefepime.
Ultimately the selection of initial antimicrobial therapy
should take into account local circumstances including the
most common potential infecting pathogen for the neu-
tropenic populations and local antimicrobial susceptibility
patterns, the patient’s infection risk assessment, the site
of infection, clinical stability, medication allergy, organ
dysfunction and previous antimicrobial therapy as well as
cost. Careful selection may enhance efﬁcacy and should
minimise the incidence of adverse events and reduce
bacterial resistance.
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